Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Leukemia 10Leukemia, Myeloid, Acute 7Congenital Abnormalities 6Glioblastoma 5Lung Neoplasms 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Gliosarcoma 4Colorectal Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Wilms Tumor 3Uterine Cervical Neoplasms 3Squamous Intraepithelial Lesions 3Myelodysplastic Syndromes 3Colonic Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Sarcoma 2Rectal Neoplasms 2Precancerous Conditions 2Ovarian Neoplasms 2Oligodendroglioma 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Kidney Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Brain Neoplasms 2

Interventions

pasireotide 7Cabergoline 7Surgical Procedures, Operative 4Temozolomide 3Propofol 3Hydrocortisone 3Dexmedetomidine 3lanreotide 2Sevoflurane 2Saline Solution 2Rosiglitazone 2Radiotherapy 2Radiosurgery 2Proton Therapy 2Octreotide 2Human Growth Hormone 2Dexamethasone 2Desflurane 2Aminolevulinic Acid 2pegvisomant 1parecoxib 1lutetium Lu 177 dotatate 1loxoprofen 1farletuzumab 1entinostat 1corticorelin ovine 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Visual Field Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Neoplasms × DNA Methylation × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡